Table 4

Crude incidence rates and adjusted HR for breast cancer among glargine users compared with NPH users according to duration of use and cumulative dose of insulin use combined

Duration of use; cumulative dose of insulin combined (units)UsersBreast cancersPY of follow-upCrude breast cancer incidence rate per 1,000 PY (95% CI)Unweighted HR (95% CI)Weighted HR (95% CI)
Glargine 0 to <3 years; 0 to <20,000203,1592,394388,4006.16 (5.92–6.41)0.98 (0.88–1.08)0.97 (0.85–1.10)
NPH 0 to <3 years; 0 to <20,00047,38847274,4316.34 (5.77–6.91)RefRef
Glargine 3 to <5 years; 0 to <20,00052,68930760,1435.10 (4.53–5.68)1.12 (0.84–1.49)1.07 (0.74–1.56)
NPH 3 to <5 years; 0 to <20,0009,2385512,0034.58 (3.37–5.79)RefRef
Glargine ≥5 years; 0 to <20,00015,66713426,5375.05 (4.19–5.90)0.81 (0.58–1.12)0.75 (0.50–1.10)
NPH ≥5 years; 0 to <20,0003,763477,5616.22 (4.44–7.99)RefRef
Glargine 0 to <3 years; 20,000 to <60,00060,81736857,0966.45 (5.79–7.10)1.03 (0.82–1.29)1.00 (0.75–1.34)
NPH 0 to <3 years; 20,000 to <60,00014,97410916,9346.44 (5.23–7.65)RefRef
Glargine 3 to <5 years; 20,000 to <60,00058,13242570,5406.02 (5.45–6.60)0.96 (0.75–1.24)0.88 (0.63–1.21)
NPH 3 to <5 years; 20,000 to <60,0009,0566810,8646.26 (4.77–7.75)RefRef
Glargine ≥5 years; 20,000 to <60,00027,75322142,1815.24 (4.55–5.93)1.55 (0.99–2.42)1.34 (0.72–2.49)
NPH ≥5 years; 20,000 to <60,0003,790216,2313.37 (1.93–4.81)RefRef
Glargine 0 to <3 years; ≥60,0003,782182,0438.81 (4.74–12.88)0.93 (0.51–1.71)0.77 (0.38–1.58)
NPH 0 to <3 years; ≥60,0002,834222,15410.21 (5.94–14.48)RefRef
Glargine 3 to <5 years; ≥60,00013,06410812,8858.38 (6.80–9.96)1.49 (0.99–2.23)1.62 (1.02–2.58)
NPH 3 to <5 years; ≥60,0004,411315,5135.62 (3.64–7.60)RefRef
Glargine ≥5 years; ≥60,00016,66519531,5176.19 (5.32–7.06)1.26 (0.89–1.78)0.99 (0.63–1.57)
NPH ≥5 years; ≥60,0003,804397,9374.91 (3.37–6.46)RefRef
  • Data are n unless otherwise indicated. Ref, reference.